Cabazitaxel in patients with advanced solid tumours: Results of a Phase i and pharmacokinetic study

European Journal of Cancer

Volumn 49, Issue 1, 2013, Pages 25-34

  Dieras V ^a   Lortholary, A ^b   Laurence, V ^a   Delva, R ^c   Girre, V ^a,d   Livartowski, A ^a   Assadourian, S ^e   Semiond, D ^e   Pierga, J Y ^a,f  

^a INSTITUT CURIE   (France)

^b Centre Catherine de Sienne   (France)

^c CENTRE PAUL PAPIN   (France)

^d Centre Hospitalier la Roche sur Yon   (France)

^e SANOFI   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cabazitaxel; Clinical trial, Phase I; Maximum tolerated dose; Pharmacokinetics; Taxoids

Indexed keywords

ANTHRACYCLINE; CABAZITAXEL; DEXCHLORPHENIRAMINE; TAXANE DERIVATIVE; VINCA ALKALOID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENDOMETRIUM CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INFECTION; LEIOMYOSARCOMA; LIMIT OF QUANTITATION; LIPOSARCOMA; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MOTOR NEURON DISEASE; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TAXOIDS;

EID: 84871455024     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.07.008     Document Type: Article

References (17)

1. K. Gelmon The taxoids: paclitaxel and docetaxel Lancet 344 1994 1267 1272 (Pubitemid 24334685)
2. E. Galletti, M. Magnani, M.L. Renzulli, and M. Botta Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes ChemMedChem 2 2007 920 942
3. M.-C. Bissery, H. Bouchard, and J.F. Riou Preclinical evaluation of TXD258, a new taxoid [abstract #1364] Proc Am Assoc Cancer Res 41 2000 214
4. B.J. Braakhuis, B.T. Hill, and M. Dietel In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells Anticancer Res 14 1994 205 208 (Pubitemid 24132114)
5. J. Hunter, M.A. Jepson, T. Tsuruo, N.L. Simmons, and B.H. Hirst Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators J Biol Chem 268 1993 14991 14997 (Pubitemid 23206648)
6. P. Vrignaud, P. Lejeune, D. Chaplin, F. Lavelle, and M.-C. Bissery In vivo efficacy of TXD258, a new taxoid, against human tumor xenografts [abstract #1365] Proc Am Assoc Cancer Res 41 2000 214
7. D.J. Dykes, J.P. Sarsat, and M.-C. Bissery Efficacy evaluation of TXD258, a taxoid compound, against orthotopic and subcutaneous glioblastomas [abstract #1916] Proc Am Assoc Cancer Res 41 2000 301
8. A.C. Mita, L.J. Denis, and E.K. Rowinsky Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors Clin Cancer Res 15 2009 723 730
9. X. Pivot, P. Koralewski, and J.L. Hidalgo A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients Ann Oncol 19 2008 1547 1552
10. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
11. P. Simon, B. Freidlin, and L. Rubinstein Accelerated titration designs for phase I clinical trials in oncology J Natl Cancer Inst 89 1997 1138 1147 (Pubitemid 27337928)
12. U.S. Department Of Health And Human Services NIoHNCI. Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0. 1999.
13. R.A. Madan, S.K. Pal, O. Sartor, and W.L. Dahut Overcoming chemotherapy resistance in prostate cancer Clin Cancer Res 17 2011 3892 3902
14. R. Bruno, N. Vivier, and J.C. Vergniol A population pharmacokinetic model for docetaxel (Taxotere): model building and validation J Pharmacokinet Biopharm 24 1996 153 172 (Pubitemid 26300483)
15. 2006 Update of ASCO practice guideline recommendations for the use of white blood call growth factors: guideline summary. J Oncol Pract 2006;2:196-201.
16. Bristol Myers Squibb. TAXOL® (paclitaxel) Injection Prescribing Information. 2011. Available from: URL: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/020262s049lbl.pdf.
17. Sanofi U.S.LLC. TAXOTERE® (docetaxel) Injection Concentrate, Intravenous Infusion (IV) Prescribing Information. 2010 May. Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/020449s059lbl.pdf.